AstraZeneca Claims Late-Stage Cancer Medication Imfinzi Improves Survival

AstraZeneca Claims Late-Stage Cancer Medication Imfinzi Improves Survival

AstraZeneca announced Thursday that patients in a trial who received its immunotherapy Imfinzi before and after surgery had considerably longer progression-free survival than those given chemotherapy.

The patients in the late-stage study had resectable, early-stage non-small cell lung cancer. They were either treated with chemotherapy before surgery or with Imfinzi as monotherapy after surgery.

AstraZeneca reported that Imfinzi was well tolerated and that there were no new safety concerns with the drug before or after surgery.

Reuters Health also covered the news on Twitter:

As of December, AstraZeneca reported that the medicine has failed to meet the primary objective of a trial in patients with advanced lung cancer.

Patients with non-small cell lung cancer who had tumor cells that exhibited high amounts of PD-L1 were examined in that late-stage study using Imfinzi as a monotherapy against platinum-based chemotherapy.

You can also follow us on our official account on Twitter to stay in touch with us.

Read the post below if you’re interested in learning more news:

 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top